Toward Peptide-Based Inhibitors as Therapies for Parkinson's Disease

References

• Spillantini MG , SchmidtML, LeeVM, TrojanowskiJQ, JakesR, GoedertM. Alpha-synuclein in lewy bodies. Nature388 (6645), 839–840 (1997).
   PubMed Web of Science ®Google Scholar
• Irvine GB , El-AgnafOM, ShankarGM, WalshDM. Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol. Med.14 (7–8), 451–464 (2008).
   PubMed Web of Science ®Google Scholar
• Conway KA , HarperJD, LansburyPT, Jr. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry39 (10), 2552–2563 (2000).
   PubMed Web of Science ®Google Scholar
• Greenbaum EA , GravesCL, Mishizen-EberzAJet al. The e46k mutation in alpha-synuclein increases amyloid fibril formation. J. Biol. Chem.280 (9), 7800–7807 (2005).
   PubMed Web of Science ®Google Scholar
• Ghosh D , MondalM, MohiteGMet al. The Parkinson's disease-associated h50q mutation accelerates alpha-synuclein aggregation in vitro. Biochemistry52 (40), 6925–6927 (2013).
   PubMed Web of Science ®Google Scholar
• Rutherford NJ , MooreBD, GoldeTE, GiassonBI. Divergent effects of the h50q and g51d snca mutations on the aggregation of alpha-synuclein. J. Neurochem.131 (6), 859–867 (2014).
   PubMed Web of Science ®Google Scholar
• Weinreb PH , ZhenWG, PoonAW, ConwayKA, LansburyPT. Nacp, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry35 (43), 13709–13715 (1996).
   PubMed Web of Science ®Google Scholar
• Bartels T , ChoiJG, SelkoeDJ. Alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature477 (7362), U107–U123 (2011).
   PubMed Web of Science ®Google Scholar
• Dettmer U , NewmanAJ, SoldnerFet al. Parkinson-causing alpha-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat. Commun.6, 7314 (2015).
   PubMed Web of Science ®Google Scholar
• Liu P , ReedMN, KotilinekLAet al. Quaternary structure defines a large class of amyloid-beta oligomers neutralized by sequestration. Cell. Rep.11 (11), 1760–1771 (2015).
   PubMed Web of Science ®Google Scholar
• Peelaerts W , BoussetL, Van Der PerrenAet al. Alpha-synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature522 (7556), 340–344 (2015).
   PubMed Web of Science ®Google Scholar
• Mason JM . Design and development of peptides and peptide mimetics as antagonists for therapeutic intervention. Future Med. Chem.2 (12), 1813–1822 (2010).
   PubMed Web of Science ®Google Scholar
• Craik DJ , FairlieDP, LirasS, PriceD. The future of peptide-based drugs. Chem. Biol. Drug. Des.81 (1), 136–147 (2013).
   PubMed Web of Science ®Google Scholar
• Madine J , DoigAJ, MiddletonDA. Design of an n-methylated peptide inhibitor of alpha-synuclein aggregation guided by solid-state NMR. J. Am. Chem. Soc.130 (25), 7873–7881 (2008).
   PubMed Web of Science ®Google Scholar
• El-Agnaf OM , PaleologouKE, GreerBet al. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J.18 (11), 1315–1317 (2004).
   PubMed Web of Science ®Google Scholar
• Shaltiel-Karyo R , Frenkel-PinterM, Egoz-MatiaNet al. Inhibiting alpha-synuclein oligomerization by stable cell-penetrating beta-synuclein fragments recovers phenotype of Parkinson's disease model flies. PLoS One5 (11), e13863 (2010).
   PubMed Web of Science ®Google Scholar
• Giasson BI , MurrayIV, TrojanowskiJQ, LeeVM. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem.276 (4), 2380–2386 (2001).
   PubMed Web of Science ®Google Scholar
• Madine J , DoigAJ, KitmittoA, MiddletonDA. Studies of the aggregation of an amyloidogenic alpha-synuclein peptide fragment. Biochem. Soc. Trans.33 (Pt 5), 1113–1115 (2005).
   PubMedGoogle Scholar
• Connelly S , ChoiS, JohnsonSM, KellyJW, WilsonIA. Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr. Opin. Struct. Biol.20 (1), 54–62 (2010).
   PubMed Web of Science ®Google Scholar
• Harrison RS , SharpePC, SinghY, FairlieDP. Amyloid peptides and proteins in review. Rev. Physiol. Biochem. Pharmacol.159, 1–77 (2007).
   PubMed Web of Science ®Google Scholar
• Singh Y , SharpePC, HoangHNet al. Amyloid formation from an alpha-helix peptide bundle is seeded by 3(10)-helix aggregates. Chemistry17 (1), 151–160 (2011).
   PubMed Web of Science ®Google Scholar
• Cheruvara H , Allen-BaumeVL, KadNM, MasonJM. Intracellular screening of a peptide library to derive a potent peptide inhibitor of alpha-synuclein aggregation. J. Biol. Chem.290 (12), 7426–7435 (2015).
   PubMed Web of Science ®Google Scholar
• Meier BH , BockmannA. The structure of fibrils from ‘misfolded’ proteins. Curr. Opin. Struct. Biol.30, 43–49 (2015).
   PubMed Web of Science ®Google Scholar